The delivery problem the team tested
A July 2026 Journal of Medicinal Chemistry paper from a team led by Yipeng Wang at the Yantai Institute of Coastal Zone Research, Chinese Academy of Sciences, examined a practical challenge for antimicrobial peptides. These molecules can kill bacteria directly, but many do not enter host cells efficiently enough to reach bacteria that persist inside them.
The researchers attached six cell penetrating peptides to HC1, an alpha helical antimicrobial peptide derived from a sea snake cathelicidin. They then compared antibacterial activity, cell uptake, intracellular bacterial clearance, biofilm activity and tolerability across the resulting conjugates.
What Bac7-HC1 added
Bac7-HC1 emerged as the leading conjugate in that screen. The published abstract reports that it was the most effective of the tested conjugates against intracellular bacterial infections, while the institute's account describes a balance of direct antibacterial potency, host cell uptake and biocompatibility.
The evidence remains preclinical. The work includes macrophage infection experiments and a mouse model of systemic Salmonella Typhimurium infection, not a human trial. Its value is as a design study for getting an antimicrobial peptide to the intracellular site of infection, rather than evidence of a treatment ready for use.
For broader laboratory context on antimicrobial peptides, explore the LL-37 research record. LL-37 was not the molecule tested in this study.